GARP on hepatic stellate cells is essential for the development of liver fibrosis
Document Type
Article
Publication Date
10-2023
Original Citation
Zhang X,
Sharma P,
Maschmeyer P,
Hu Y,
Lou M,
Kim J,
Fujii H,
Unutmaz D,
Schwabe RF,
Winau F.
GARP on hepatic stellate cells is essential for the development of liver fibrosis J Hepatol. 2023;79(5):1214-25.
Keywords
JGM
JAX Source
J Hepatol. 2023;79(5):1214-25.
DOI
https://doi.org/10.1016/j.jhep.2023.05.043
Abstract
BACKGROUND & AIMS: Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-beta docking molecule. While the immune regulatory properties of GARP on blood cells have been studied, the function of GARP on tissue stromal cells remains unclear. Here, we investigate the role of GARP expressed on hepatic stellate cells (HSCs) in the development of liver fibrosis. METHODS: The function of GARP on HSCs was explored in toxin-induced and metabolic liver fibrosis models, using conditional GARP-deficient mice or a newly generated inducible system for HSC-specific gene ablation. Primary mouse and human HSCs were isolated to evaluate the contribution of GARP to the activation of latent TGF-beta. Moreover, cell contraction of HSCs in the context of TGF-beta activation was tested in a GARP-dependent fashion. RESULTS: Mice lacking GARP in HSCs were protected from developing liver fibrosis. Therapeutically deleting GARP on HSCs alleviated the fibrotic process in established disease. Furthermore, natural killer T cells exacerbated hepatic fibrosis by inducing GARP expression on HSCs through IL-4 production. Mechanistically, GARP facilitated fibrogenesis by activating TGF-beta and enhancing endothelin-1-mediated HSC contraction. Functional GARP was expressed on human HSCs and significantly upregulated in the livers of patients with fibrosis. Lastly, deletion of GARP on HSCs did not augment inflammation or liver damage. CONCLUSIONS: GARP expressed on HSCs drives the development of liver fibrosis via cell contraction-mediated activation of latent TGF-beta. Considering that systemic blockade of TGF-beta has major side effects, we highlight a therapeutic niche provided by GARP and surface-mediated TGF-beta activation. Thus, our findings suggest an important role of GARP on HSCs as a promising target for the treatment of liver fibrosis. IMPACT AND IMPLICATIONS: Liver fibrosis represents a substantial and increasing public health burden globally, for which specific treatments are not available. Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-beta docking molecule. Here, we show that GARP expressed on hepatic stellate cells drives the development of liver fibrosis. Our findings suggest GARP as a novel target for the treatment of fibrotic disease.